secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2023-01-17T23:59:59+00:00
Accession:  0001104659-23-004066
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics acquires Flame Biosciences, gaining FL-301 and ~$50M net cash, combined cash ~$115M
--------------------------------------------------------------------------------

- Acquired Flame for ~19.8M shares common + ~136.8k Series X preferred (convertible to 1,000 common each).
- Combined cash ~$115M (incl. ~$50M net from Flame) expected to fund operations to mid-2025.
- Pipeline adds clinical anti-Claudin18.2 antibody FL-301 and preclinical FL-302/FL-501 programs.
- Flame shareholders to own 58% of pro forma shares (as-converted), pending stockholder approval of conversion.
- Board expanded to include Patricia Martin and Christian Richard; existing management remains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923004066/0001104659-23-004066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923004066/tm233557d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-004066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer